UNLABELLED: Although prolonged-release tacrolimus (PR-T) is widely approved for posttransplantation immunosuppression in kidney recipients, large-scale studies are required to assess long-term outcomes. We present follow-up data from the Advagraf-based Immunosuppression Regimen Examining New Onset Diabetes Mellitus in Kidney Transplant Recipients (ADVANCE) trial, in which kidney transplant patients (KTPs) received corticosteroid minimization with PR-T. METHODS: ADVANCE was a 24-wk, randomized, open-label, phase-4 study. De novo KTPs received PR-T with basiliximab and mycophenolate mofetil and were randomized to receive an intraoperative corticosteroid bolus plus tapered corticosteroids until day 10 (arm 1) or an intraoperative corticosteroid bolus (arm 2). In this 5-y, noninterventional follow-up, patients received maintenance immunosuppression according to standard practice. The primary endpoint was graft survival (Kaplan-Meier). Secondary endpoints included patient survival, biopsy-confirmed acute rejection-free survival, and estimated glomerular filtration rate (4-variable modification of diet in renal disease). RESULTS: Follow-up study included 1125 patients. Overall graft survival at 1 and 5 y posttransplantation was 93.8% and 88.1%, respectively, and was similar between treatment arms. At 1 and 5 y, patient survival was 97.8% and 94.4%, respectively. Five-year graft and patient survival rates in KTPs who remained on PR-T were 91.5% and 98.2%, respectively. Cox proportional hazards analysis demonstrated similar risk of graft loss and death between treatment arms. Five-year biopsy-confirmed acute rejection-free survival was 84.1%. Mean ± standard deviation values of estimated glomerular filtration rate were 52.7 ± 19.5 and 51.1 ± 22.4 mL/min/1.73 m2 at 1 and 5 y, respectively. Fifty adverse drug reactions were recorded, probably tacrolimus-related in 12 patients (1.5%). CONCLUSIONS: Graft survival and patient survival (overall and for KTPs who remained on PR-T) were numerically high and similar between treatment arms at 5 y posttransplantation.

BENKAZ Consulting Ltd Cambridge United Kingdom

Department of Infectious Diseases West German Centre of Infectious Diseases University Hospital Essen University Duisberg Essen Germany

Department of Nephrology and Renal Transplantation University Hospitals Leuven Leuven Belgium

Department of Nephrology Dialysis and Transplantation Hôpital Lapeyronie University of Montpellier Montpellier France

Department of Nephrology Transplant Center Institute for Clinical and Experimental Medicine Prague Czech Republic

Department of Surgical Sciences Division of Transplantation Surgery Uppsala University Hospital Uppsala Sweden

Department of Transplantation Surgery Karolinska University Hospital Stockholm Sweden

Department of Transplantology and Surgery District Public Hospital Collegium Medicum in Bydgoszcz Nicolaus Copernicus University Bydgoszcz Poland

Department of Urology and Kidney Transplantation Clinic of Surgery Tartu University Hospital Tartu Estonia

Medical Affairs Astellas Pharma Europe Chertsey United Kingdom

Zobrazit více v PubMed

Garcia GG, Harden P, Chapman J; World Kidney Day Steering Committee 2012. The global role of kidney transplantation. Curr Opin Organ Transplant. 2012;17:362–367. PubMed

Rana A, Gruessner A, Agopian VG, et al. . Survival benefit of solid-organ transplant in the United States. JAMA Surg. 2015;150:252–259. PubMed

James A, Mannon RB. The cost of transplant immunosuppressant therapy: is this sustainable? Curr Transplant Rep. 2015;2:113–121. PubMed PMC

Gaston RS. Improving long-term outcomes in kidney transplantation: towards a new paradigm of post-transplant care in the United States. Trans Am Clin Clim Assoc. 2016;127:350–361. PubMed PMC

Gondos A, Döhler B, Brenner H, et al. . Kidney graft survival in Europe and the United States: strikingly different long-term outcomes. Transplantation. 2013;95:267–274. PubMed

Kramer A, Pippias M, Stel VS, et al. . Renal replacement therapy in Europe: a summary of the 2013 ERA-EDTA Registry Annual Report with a focus on diabetes mellitus. Clin Kidney J. 2016;9:457–469. PubMed PMC

Kalluri HV, Hardinger KL. Current state of renal transplant immunosuppression: present and future. World J Transplant. 2012;2:51–68. PubMed PMC

Hart A, Smith JM, Skeans MA, et al. . OPTN/SRTR 2017 annual data report: kidney. Am J Transplant. 2019;19:19–123. PubMed

Caillard S, Moulin B, Buron F, et al. . Advagraf®, a once-daily prolonged release tacrolimus formulation, in kidney transplantation: literature review and guidelines from a panel of experts. Transpl Int. 2016;29:860–869. PubMed

Tedesco-Silva H, Jr, Yang HC, Meier-Kriesche HU, et al. . Long-term follow-up of a Phase III clinical trial comparing tacrolimus extended-release/MMF, tacrolimus/MMF, and cyclosporine/MMF in de novo kidney transplant recipients. Transplantation. 2014;97:636–641. PubMed PMC

Krämer BK, Charpentier B, Bäckman L, et al. ; Tacrolimus Prolonged Release Renal Study Group. Tacrolimus once daily (ADVAGRAF) versus twice daily (PROGRAF) in de novo renal transplantation: a randomized Phase III study. Am J Transplant. 2010;10:2632–2643. PubMed

Tsuchiya T, Ishida H, Tanabe T, et al. . Comparison of pharmacokinetics and pathology for low-dose tacrolimus once-daily and twice-daily in living kidney transplantation: prospective trial in once-daily versus twice-daily tacrolimus. Transplantation. 2013;96:198–204. PubMed

Albano L, Banas B, Klempnauer JL, et al. ; Optimising immunoSuppression After Kidney transplantation with ADVAGRAF Study Group. OSAKA trial: a randomized, controlled trial comparing tacrolimus QD and BD in kidney transplantation. Transplantation. 2013;96:897–903. PubMed PMC

Kuypers DRJ, Peeters PC, Sennesael JJ, et al. ; ADMIRAD Study Team. Improved adherence to tacrolimus once-daily formulation in renal recipients: a randomized controlled trial using electronic monitoring. Transplantation. 2013;95:333–340. PubMed

Wu MJ, Cheng CY, Chen CH, et al. . Lower variability of tacrolimus trough concentration after conversion from Prograf to Advagraf in stable kidney transplant recipients. Transplantation. 2011;92:648–652. PubMed

Stifft F, Stolk LM, Undre N, et al. . Lower variability in 24-hour exposure during once-daily compared to twice-daily tacrolimus formulation in kidney transplantation. Transplantation. 2014;97:775–780. PubMed

Mourad G, Glyda M, Albano L, et al. ; Advagraf-based immunosuppression regimen examining new onset diabetes mellitus in kidney transplant recipients (ADVANCE) study investigators. Incidence of posttransplantation diabetes mellitus in de novo kidney transplant recipients receiving prolonged-release tacrolimus-based immunosuppression with 2 different corticosteroid minimization strategies: ADVANCE, a randomized controlled trial. Transplantation. 2017;101:1924–1934. PubMed PMC

Solez K, Colvin RB, Racusen LC, et al. . Banff 07 classification of renal allograft pathology: updates and future directions. Am J Transplant. 2008;8:753–760. PubMed

Hallan S, Asberg A, Lindberg M, et al. . Validation of the modification of diet in renal disease formula for estimating GFR with special emphasis on calibration of the serum creatinine assay. Am J Kidney Dis. 2004;44:84–93. PubMed

van den Brand JAJG, van Boekel GAJ, Willems HL, et al. . Introduction of the CKD-EPI equation to estimate glomerular filtration rate in a Caucasian population. Nephrol Dial Transplant. 2011;26:3176–3181. PubMed

Cockcroft DW, Gault M. Prediction of creatinine clearance from serum creatinine. Nephron. 1976;16:31–41. PubMed

Kaplan EL, Meier P. Nonparametric estimation from incomplete observations. J Am Stat Assoc. 1958;53:457–481.

van Hooff JP, Alloway RR, Trunečka P, et al. . Four-year experience with tacrolimus once-daily prolonged release in patients from Phase II conversion and de novo kidney, liver, and heart studies. Clin Transplant. 2011;25:E1–12. PubMed

Rummo O, Carmellini M, Kamar N, et al. . Long-term prolonged-release tacrolimus-based immunosuppression in de novo kidney transplant recipients: 5-year prospective follow-up of the ADHERE study patients. Transpl Int. 2020;33:161–173. PubMed

Wakasugi N, Uchida H, Uno S. Safety and effectiveness of once-daily, prolonged-release tacrolimus in de novo kidney transplant recipients: 5-year, multicenter postmarketing surveillance in Japan. Transplant Proc. 2018;50:3296–3305. PubMed

Jalalzadeh M, Mousavinasab N, Peyrovi S, et al. . The impact of acute rejection in kidney transplantation on long-term allograft and patient outcome. Nephrourol Mon. 2015;7:e24439. PubMed PMC

Wiebe C, Gibson IW, Blydt-Hansen TD, et al. . Evolution and clinical pathologic correlations of de novo donor-specific HLA antibody post kidney transplant. Am J Transplant. 2012;12:1157–1167. PubMed

Choi HY, Huh KH, Lee JG, et al. . Variability of the estimated glomerular filtration rate in the first year after kidney transplantation is an independent risk factor for poor renal allograft outcomes: a retrospective cohort study. PLoS One. 2016;11:e0168337. PubMed PMC

Ekberg H, Bernasconi C, Tedesco-Silva H, et al. . Calcineurin inhibitor minimization in the Symphony study: observational results 3 years after transplantation. Am J Transplant. 2009;9:1876–1885. PubMed

van Duijnhoven EM, Boots JMM, Christiaans MHL, et al. . Increase in tacrolimus trough levels after steroid withdrawal. Transpl Int. 2003;16:721–725. PubMed

Stifft F, van Kuijk SMJ, Bekers O, et al. . Increase in tacrolimus exposure after steroid tapering is influenced by CYP3A5 and pregnane X receptor genetic polymorphisms in renal transplant recipients. Nephrol Dial Transplant. 2018;33:1668–1675. PubMed

Vanrenterghem Y, van Hooff JP, Squifflet JP, et al. ; European Tacrolimus/MMF Renal Transplantation Study Group. Minimization of immunosuppressive therapy after renal transplantation: results of a randomized controlled trial. Am J Transplant. 2005;5:87–95. PubMed

Opelz G. Effect of the maintenance immunosuppressive drug regimen on kidney transplant outcome. Transplantation. 1994;58:443–446. PubMed

Opelz G, Döhler B, Laux G; Collaborative Transplant Study. Long-term prospective study of steroid withdrawal in kidney and heart transplant recipients. Am J Transplant. 2005;5:720–728. PubMed

Haller MC, Royuela A, Nagler E, et al. . Steroid avoidance or withdrawal for kidney transplant recipients. In: Haller MC, ed. Cochrane Database of Systematic Reviews. John Wiley & Sons; 2016:CD005632. PubMed PMC

Knight SR, Morris PJ. Steroid avoidance or withdrawal after renal transplantation increases the risk of acute rejection but decreases cardiovascular risk. A meta-analysis. Transplantation. 2010;89:1–14. PubMed

Pascual J, Galeano C, Royuela A, et al. . A systematic review on steroid withdrawal between 3 and 6 months after kidney transplantation. Transplantation. 2010;90:343–349. PubMed

Pascual J, Royuela A, Galeano C, et al. . Very early steroid withdrawal or complete avoidance for kidney transplant recipients: a systematic review. Nephrol Dial Transplant. 2012;27:825–832. PubMed

Ghisdal L, Van Laecke S, Abramowicz MJ, et al. . New-onset diabetes after renal transplantation: risk assessment and management. Diabetes Care. 2012;35:181–188. PubMed PMC

Thomusch O, Wiesener M, Opgenoorth M, et al. . Rabbit-ATG or basiliximab induction for rapid steroid withdrawal after renal transplantation (harmony): an open-label, multicentre, randomised controlled trial. Lancet. 2016;388:3006–3016. PubMed

Montero N, Pascual J. Immunosuppression and post-transplant hyperglyceamia. Curr Diabetes Rev. 2015;11:144–154. PubMed

Woodle ES, First MR, Pirsch J, et al. ; Astellas Corticosteroid Withdrawal Study Group. A prospective, randomized, double-blind, placebo-controlled multicenter trial comparing early (7 day) corticosteroid cessation versus long-term, low-dose corticosteroid therapy. Ann Surg. 2008;248:564–577. PubMed

Wadström J, Ericzon BG, Halloran PF, et al. . Advancing transplantation: new questions, new possibilities in kidney and liver transplantation. Transplantation. 2017;101:S1–S41. PubMed

Kuypers DRJ. Intrapatient variability of tacrolimus exposure in solid organ transplantation: a novel marker for clinical outcome. Clin Pharmacol Ther. 2020;107:347–358. PubMed

Loupy A, Hill GS, Jordan SC. The impact of donor-specific anti-HLA antibodies on late kidney allograft failure. Nat Rev Nephrol. 2012;8:348–357. PubMed